Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pamrevlumab + gemcitabine + nab-paclitaxel or pamrevlumab + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- FibroGen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Pamrevlumab is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF), a key mediator of fibrosis and tumor progression. By binding to CTGF, pamrevlumab inhibits its activity and prevents downstream signaling involved in fibrotic and neoplastic processes[1][2][3]. In oncology settings such as pancreatic cancer, it is being investigated in combination with standard chemotherapy regimens including gemcitabine plus nab-paclitaxel or FOLFIRINOX. Gemcitabine is a nucleoside analog used as chemotherapy; nab-paclitaxel (Abraxane) is an albumin-bound formulation of paclitaxel; FOLFIRINOX combines folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin. The combination aims to enhance antitumor efficacy by targeting both the tumor microenvironment via anti-fibrotic action and directly attacking cancer cells with cytotoxic agents[6].
- Brand names
- Abraxane (nab-paclitaxel)
02
Targets
RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))CTGF (Connective tissue growth factor)DNA polymerase familyTOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on pamrevlumab + gemcitabine + nab-paclitaxel or pamrevlumab + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pamrevlumab + gemcitabine + nab-paclitaxel or pamrevlumab + FOLFIRINOX.